Halda Therapeutics Raises $126 Million (Series B) To Advance Cancer Therapies
By Amit Chowdhry ● Aug 12, 2024
Halda Therapeutics, a biotechnology company developing a novel class of cancer therapies called RIPTAC (Regulated Induced Proximity TArgeting Chimeras) therapeutics, announced today that it has raised new financing of $126 million in a Series B extension, including funding from new investors Deep Track Capital, Frazier Life Sciences, RA Capital Management, Vida Ventures, Boxer Capital and Taiho Ventures, as well as existing investors Canaan Partners, Access Biotechnology, Elm Street Ventures, and Connecticut Innovations. With this funding round, Halda has raised $202 million to date from investors.